TP53 and non-small cell lung carcinoma: The concurrent mutations, such as TP53, STK11 (LKB1), KEAP1, and ATM, might contribute to the diverse response observed in KRAS‐mutant NSCLC.18 In 2015, Skoulidis et al summarized characteristics of three KRAS co‐mutation subtypes: KP vs KL vs KC.12 In 2017, Arbour et al reported the unfavorable survival of KRAS‐mutant patients with concurrent KEAP1 alteration, which belonged to a new stratification: KP vs KL vs KK.11 In our study, we discovered a new subtype: KPL (KRAS mutation with TP53 and LKB1 mutated) which had the most unfavorable PFS among all KRAS mutation subtypes.